Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ascendis Pharma (ASND): OrbiMed Advisors Adds More Shares

Page 1 of 12

Samuel Isaly just cannot get enough of Ascendis Pharma A/S (NASDAQ:ASND). According to an amended filing with the Securities and Exchange Commission, Isaly’s OrbiMed Advisors has recently acquired 371,514 shares of Ascendis, taking its tally to 3.67 million shares or 14.6% of the company’s outstanding stock. The fund has been actively buying Ascendis shares this quarter, having held only 222,223 shares at the end of March.

Based in Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a clinical stage biotech company that develops a number of prodrug therapies to address such deficiencies as growth hormone deficiency, pulmonary arterial hypertension and others. So far this year, the stock has been mostly in the red, falling by 26% to yesterday’s closing price of $13.27 per share. The company’s poor first quarter performance only made matters worse and put more pressure on the stock. Ascendis registered a loss of €0.82 ($0.92) per share and revenues of €1.3 million ($1.46 million), down by 40% year-over-year.

Samuel Isaly Orbimed Advisors

Ascendis Pharma A/S (NASDAQ:ASND) is not a very popular stock among the funds tracked by Insider Monkey, with only 10 of them having reported a stake in the company at the end of the first quarter, down from 11 registered at the end of December. Of the most prominent investors, Peter Kolchinsky and RA Capital Management had a sizable position in Ascendis Pharma, which amounted to 2.16 million shares. Julian Baker and Felix Baker‘s Baker Bros. Advisors held a more modest stake: 505,521 shares, unchanged over the course of the first quarter.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 3,671,976 0 3,671,976 3,671,976 14.6%
OrbiMed Capital GP V 0 3,671,976 0 3,671,976 3,671,976 14.6%
Samuel D. Isaly 0 3,671,976 0 3,671,976 3,671,976 14.6%
Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Page 1 of 12 – SEC Filing



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)

ASCENDIS PHARMA A/S


(Name of Issuer)

Ordinary Shares


(Title of Class of Securities)
04351P101
(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022

Telephone: (212) 739-6400


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 28, 2016


(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 



Follow Ascendis Pharma A/s
Trade () Now!
Page 1 of 12

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!